Our Value for

Medytox Vision 2022

- Integrity
- Commitment & Courage
- Global Standard & Pride
- Open Communication

Biotechnology that Changes The Future
Medytox is a biopharmaceutical company that changes the future
Pioneer of Biopharmaceutical Industry

1. The only biopharmaceutical company in the world to have three different types of botulinum toxin products (Neuronox®, INNOTOX®, Coretox®), all developed by in-house R&D
   
   I. First company in Korea and fourth company worldwide to develop a botulinum toxin type A product
   II. Development of the world’s first liquid formulation of botulinum toxin type A product with no animal-derived ingredients
   III. Development of purified botulinum toxin type A product, which contains only the core active ingredient, and no animal-derived substances

2. Development of various hyaluronic acid dermal filler

3. Out-licensing of the new formulation botulinum toxin type A product to Allergan Inc. (Deal size: $362 million)

4. Disclosure of the entire genome sequence of strain of Clostridium botulinum at Medytox for the first time in botulinum toxin market

Global Biopharmaceutical Company

1. Export of botulinum toxin type A and HA filler products to over 60 countries

2. Development of the next generation biopharmaceutical products

3. Penetration into advanced markets such as US and EU
Greetings!

My name is Jung Hyunho, and I’m the CEO of Medytox. Thanks to your support, Medytox has expanded beyond domestic boundaries and is now one of the premier companies in the global botulinum toxin market. For this, I would like to express my sincere appreciation and gratitude.

Medytox has grown by pushing for innovations and continually challenging ourselves. As the first botulinum toxin developer and the market leader in Korea, we feel a sense of pride and responsibility for this industry, which is why we are leading the efforts to improve the transparency and the competitiveness of the Korean biopharmaceutical businesses by pushing for implementation of more objective and scientific guidelines for industry practice.

Additionally, by maintaining its focus on continual in-house R&D, Medytox has developed three different types of botulinum toxin products, Neuronox®, INNOTOX® and Coretox®, each with its own unique strengths. Along with these products, Medytox has introduced Neuramis®, successfully solidifying a new pipeline of dermal fillers.

In 2016, Medytox exceeded the 100 billion KRW mark in total annual sales for the first time since its founding. Neuronox® has become the No.1 product in its category in both Japan and Thailand, followed by Korea market. Last December, KGMP and product approval (Neuronox® for export) for plant III were obtained, relieving the supply constraint concern.

Neuramis® also has contributed to the rapid growth in sales. Since its launch in 2013, sales of Neuramis® have reached over 4 million in quantity, proving its efficacy and safety, and establishing itself as reputable product in the global market.

Medytox, as a company striving to change the future, has set a new goal of entering the Top 20 list of biopharma companies by 2022. In order to achieve this goal, everyone at Medytox is stepping up their efforts to tackle the advanced markets as well as expand the direct penetration of emerging markets. Additionally, we will continue to increase the R&D investment, develop new businesses, and always seek new acquisition opportunities to create synergy.

Medytox will continue to live up to our reputation as innovators in the biopharma industry, and in all aspects of our business. We are committed to maintaining high standards worthy of global recognition. We sincerely ask for your continuous support, love and encouragement. Thank you.
Since botulinum toxin type A Neuronox® (being sold worldwide under different brand names such as Siax®, Botulift®, Cunox®, Tonytox® and Meditoxin®) was launched in 2006, Medytox has shown a dramatic growth. Since 2009, Medytox has ranked No.1 in its market share in Korea and reached nearly 40% of market share. As additional efficacies are discovered, it is predicted that the market share will increase even further.

The global botulinum toxin market has been on the rise (approximately 13.4% growth per year). It is likely that botulinum toxin market will further expand to therapeutic market as well as medical aesthetics market. Even though Medytox is considered a new player, it has surprised many with a significant market share gain in a short time.

Medytox, as a company striving to change the future, has set goals of achieving 1 billion dollars in sales and entering the Top 20 list of biopharma companies by 2022.

To that end, Medytox is stepping up its efforts to tackle the advanced markets as well as expand the direct penetration of emerging markets. Additionally, we will continue to increase the R&D investment, develop new businesses, and seek new acquisition opportunities to create synergy.
Since the successful development of the fourth botulinum toxin type A product in the world, Medytox has continued moving forward by establishing a presence in medical aesthetics as well as therapeutic indications, associated with movement disorder and it continues to innovate.

Medytox was able to launch a HA Filler Neuramis® Series, which could generate synergy with botulinum toxin products, and also launched the world's first liquid formulation botulinum toxin type A product INNOTOX® in Korea and Japan. Medytox also has obtained Coretox® marketing approval in 2016, which is the 3rd botulinum toxin type A product for the company.

Medytox has raised the bar for the Korean biopharma industry by signing a $362million out-license contract with Allergan, maker of Botox, in September of 2013. Medytox exports its products to over 60 countries including Japan, Brazil, Thailand and Iran. Moreover, Medytox is making efforts to penetrate the US and European market in the near future. Ultimately, Medytox is working ceaselessly with the goal of becoming a leading global biopharmaceutical company.

Recently, Medytox has started shifting its gear, from indirect penetration through local agent basis export to direct market penetration for overseas expansion, and has set up several joint ventures, including Medytox Taiwan, Medybloom China, Medytox Hong Kong, and MedyCeles in Thailand respectively, as well as a subsidiary, MDT International, in Japan. The new penetration strategy is expected to bring more growth and profitability in the global market.
**INNOTOX®**

The Innovation of Botulinum Toxin Type A

1. **The World’s First Liquid Formulation of Botulinum Toxin Type A**
   - The world’s first liquid formulation of botulinum toxin type A product with no animal-derived ingredients.

2. **User Friendly**
   - Enhanced user convenience without dilution process, which minimizes potential hygiene problems.

3. **Proven Efficacy & Safety**
   - Efficacy and safety proven in clinical study. Ref 1

4. **Accurate Dose**
   - Exact dose for injection (INNOTOX® 0.1mL = 4unit)

INNOTOX® is the world’s first liquid formulation of botulinum toxin type A product, developed and launched in 2014.

INNOTOX® is an innovative product which has been developed by totally excluding animal-derived ingredients and human serum albumin in order to enhance product safety. At the same time, it is easy to prepare since no dilution is necessary for administration.

Currently INNOTOX® is being sold in Korea and Japan and it is emerging as the product to show our distinguished R&D capabilities.
Neuronox® is Korea’s first and the fourth botulinum toxin type A product in the world, launched in 2006.

Neuronox® is a representative botulinum toxin type A product of Medytox that is being exported to over 60 countries. Neuronox® ranks No.1 in market share in Korea and has gained significant market share in many other countries. (Being sold worldwide under different brand names including Siax®, Botulift®, Cunox®, Tonytox® and Meditoxin®).

(Registered in 30 countries, Registration in progress in 30 additional countries)

1 Proven Efficacy & Safety

Efficacy and safety proven in clinical studies, with results published in distinguished academic journal such as Dermatologic Surgery.

2 Global Product

Neuronox® has been sold in over 60 countries, since its first launch in 2006. Neuronox® is being sold worldwide under different brand names, such as Siax®, Botulift®, Cunox®, Tonytox® and Meditoxin®. (Registered in 30 countries, Registration in progress in 30 additional countries)

3 Various choices

Neuronox® line consists of 50, 100, 150 and 200 units, offering various choices according to the application. Physicians find it easier to use and the patients, more economical.

Neuronox® offers choices by providing a range of product units including 50, 100, 150 and 200.

Backed up by efficacy and safety proven through clinical trials, Neuronox® has recently reached the sales of over 5 million vials*, and the sales is still steadily growing.

* Figures from Medytox (2016.04)
Medytox has obtained Coretox® marketing approval in 2016, which was developed as the 3rd botulinum toxin type A product for the company.

Coretox® is an advanced new botulinum toxin type A product that excludes animal derivatives, HSA and non-toxin proteins from its ingredients. It prevents the immune system from developing antibodies that would eventually wear down the effects of botulinum toxin type A.
Neuramis® is the hyaluronic acid dermal filler product developed and launched in 2011. The Neuramis® series Neuramis® Meso (Export Only), Neuramis® Light Lidocaine, Neuramis® Lidocaine, Neuramis® Deep, Neuramis® Deep Lidocaine, Neuramis® Volume Lidocaine which can be used to add volume and fullness to the skin to correct moderate to severe nasolabial folds, the lines from your nose to the corners of your mouth.

Neuramis® Deep attained CE mark in 2011 and other series are in the process as well.
R&D

Botulinum toxin, one of the neurotoxins produced by Clostridium botulinum, is known as the most toxic substance in nature. It is widely used not only in the medical aesthetics field, including facial wrinkle reduction, but also in the therapeutic field for patients with blepharospasm, strabismus, cerebral palsy, etc.

In 2000, a group of Korean botulinum toxin experts with world-class expertise joined together to start a business with the common vision of localizing botulinum toxin production. This was the beginning of Medytox.

The Microbial Toxin R&D Center at Medytox, which was established in 2001, specializes in various areas of biotech R&D, including the development of botulinum toxin products. It is now leading the Korean biotech industry by fostering expert researchers and developing advanced technologies.

Based on its advanced technology, Medytox has successfully commercialized botulinum toxin type A formulation, the fourth in the world. Medytox has continually invested in R&D, built advanced biopharmaceuticals-related GMP facilities, and recruited highly talented personnel with experience in clinical trials and international sales.

Medytox strongly believes that these continued efforts and passion to develop biotechnology will help to create more advanced, healthier, and happier lives for everyone.
To achieve this, Medytox has made a large-scale investment to establish a R&D center for the development of high quality biopharmaceuticals. Simultaneously, Medytox has recruited top talents in the biopharmaceutical sector to strengthen our foundation, along with the growth numbers.

Moving beyond Korea, Medytox aims to be the No.1 biopharmaceutical company globally.

To achieve this, Medytox has made a large-scale investment to establish a R&D center for the development of high quality biopharmaceuticals. Simultaneously, Medytox has recruited top talents in the biopharmaceutical sector to strengthen our foundation, along with the growth numbers.

Through its new R&D center, which is scheduled for completion this year, Medytox hopes to provide innovative and life-changing biopharmaceutical products for consumers everywhere.
Medytox Plant I (Ochang), a botulinum toxin and HA filler manufacturing facility, obtained GMP approval for biologics and injectable from MFDS (Formerly KFDA) in 2004.

This plant was designed as a dedicated facility for manufacture of the botulinum toxin, as well as the final product. HA Filler production facility received ISO13485 (medical device) approval in 2010 and CE mark in 2011.

Medytox Plant I is deeply committed to the manufacturing of highest quality products for consumers everywhere.
Medytox, with global expansion in mind, established the Medytox Plant II (Osong), which is dedicated to toxin production for the penetration of the U.S. and the European markets.

Medytox Plant II will play a leading role in producing and supplying innovative botulinum toxin products intended for the global market.

Currently, the validation to meet cGMP / EU GMP certification requirement has been completed. With the manufacturing capacity at Medytox Plant II, we expect tremendous growth in production and sales.
Medytox Plant III at Osong obtained KGMP approval for toxin facility last December.

Medytox Plant III is a cGMP/ EU GMP compliant facility for production of both botulinum toxin product and HA filler. It will supplement the production quantity to meet the increasing market demand and provide additional capacity to allow for the entry into developed markets such as the US and the EU.

102, Osongsaengmyeong 4-ro, Yeonje-ri, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, Republic of Korea
Contact Information

Medytox Plant I (Ochang)
78, Gangni 1-gil, Ochang-eup, Cheongwon-gu, Cheongju-si, Chungcheongbuk-do, Republic of Korea
T 043 217 1555
F 043 217 1557

Medytox Plant II (Osong)
71, Osongsangmyeong 6-ro, Mansu ri, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, Republic of Korea
T 043 217 1555
F 043 217 1557

Medytox Plant III (Osong)
102, Osongsangmyeong 4-ro, Yeonje ri, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, Republic of Korea
T 043 217 1555
F 043 217 1557

Medytox Bldg.
Medytox Bldg., 626, Teheran-ro, Gangnam-gu, Seoul, Republic of Korea
T 02 3471 8319
F 02 3476 8372

Medytox Korea Seoul Office
F8, 626, Teheran-ro, Gangnam-gu, Seoul, Republic of Korea
T 080 850 2006
F 02 535 8334

Medytox US Office
20271, Goldenrod Lane, suite 2080/2082, Germantown, MD, 20876
T +1 301 972 0810
F +1 301 972 0682

MDT International (Japan)
6F, Hamamatsucho West BLDG, 2-10-4, Shibakoen, Minato-ku, Tokyo, Japan
T +81 3 6452 9606
F +81 3 6452 9608

Medytox R&D Center (Osong)
71, Osongsangmyeong 6-ro, Mansu ri, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, Republic of Korea
T 043 217 1555
F 043 217 1557

Medytox R&D Center (Gwanggyo)
1322-8, Ilri-dong, Yeongtong-gu, Suwon-si, Gyonggi-do, Republic of Korea
T 070 8666 7796
F 043 217 1557

Global Business junlee@medytox.com
Licensing In/Out junghwan.kim@medytox.com
R&D chrhee@medytox.com
IR sh@medytox.com / hjchang@medytox.com
Media Inquiries comm@medytox.com
Human Resource recruit@medytox.com
Medytox Korea ksoh@medytox.com
Medytox US yanggh@medytox.com
MDT International (Japan) kiwey23@medytox.com
Medybloom China yspark@medytox.com
Medytox Taiwan yspark@medytox.com
Medytox Hong Kong yspark@medytox.com
MedyCeles (Thailand) chung.w@medytox.com